Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers. A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 111, Issue 3, 2008, Pages 487-495

  Darcy, Kathleen M ^a   Brady, William E ^a   McBroom, John W ^b   Bell, Jeffrey G ^c   Young, Robert C ^d   McGuire, William P ^e   Linnoila, R Ilona ^f   Hendricks, Denver ^f   Bonome, Tomas ^f   Farley, John H ^g  

^a Buffalo Niagara Enterprise   (United States)

^b GOG Hawaii MCCOP   (United States)

^c RIVERSIDE METHODIST HOSPITAL   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e Harry and Jeanette Weinberg Cancer Institute   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

IHC; Ovarian cancer; Overexpression; p53; Prognostic markers

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RISK FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 56749098120     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.08.020     Document Type: Article

References (48)

1. Jemal A., Siegel R., Ward E., Murray R., Xu J., and Thun M. Cancer statistics, 2007. CA - A Cancer J. Clin. 57 (2007) 43-66
2. Hainaut P., Hernandez T., Robinson A., et al. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualization tools. Nucleic Acids Res. 26 (1998) 205-213
3. Petitjean A., Achatz M.I., Borresen-Dale A.L., Hainaut P., and Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (2007) 2157-2165
4. Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene 26 (2007) 2145-2156
5. May P., and May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18 (1999) 7621-7636
6. Oren M., and Rotter V. Introduction: p53 - the first twenty years. Cell Mol. Life Sci. 55 (1999) 9-11
7. Bourdon J.C. p53 and its isoforms in cancer. Br. J. Cancer 97 (2007) 277-282
8. Marks J., Davidoff A., Kerns B., et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 51 (1991) 2979-2984
9. Kihana T., Tsuda H., Teshima S., Okada S., Matsuura S., and Horohashi S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn. J. Cancer Res. 83 (1992) 978-984
10. Kohler M.F., Kerns B.-J.M., Humphrey P.A., Marks J.R., Bast Jr. R.C., and Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet. Gynecol. 81 (1993) 643-650
11. Berchuck A., Kohler M.F., Marks J.R., Wiseman R., Boyd J., and Bast Jr. R.C. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol. 170 (1994) 246-252
12. Hartmann L.C., Podratz K.C., Keeney G.L., et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J. Clin. Oncol. 12 (1994) 64-69
13. Henriksen R., Stang P., Wilander E., Backstrom T., Tribukait B., and Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol. Oncol. 53 (1994) 301-306
14. Sheridan E., Silcocks P., Smith J., Hancock B.W., and Goyns M.H. P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. Eur. J. Cancer 30A (1994) 1701-1704
15. Klemi P.-J., Pylkkanen L., Kiilhoma P., Kurvinen K., and Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76 (1995) 1201-1208
16. van der Zee A.G.J., Hollema H., Suurmeijer A.J.H., et al. Value of P-Glycoprotein, glutathione S-transferase pi, c-erb B-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol. 13 (1995) 70-78
17. Allan I.A., Campbell M.K., Milner B.J., et al. The significance of p53 mutation and over-expression in ovarian cancer prognosis. Int. J. Gynecol. Cancer 6 (1996) 483-490
18. Righetti S.C., Torre G.D., Pilotti S., et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56 (1996) 689-693
19. Eltabbakh G.H., Belinson J.L., Kennedy A.W., et al. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 80 (1997) 892-898
20. Geisler J., Geisler H., Wiemann M., et al. Quantification of p53 in epithelial ovarian cancer. Gynecol. Oncol. 66 (1997) 435-438
21. Ioakim-Liossi A., Karakitsos P., Aroni K., et al. p53 protein expression and DNA ploidy in common epithelial tumors of the ovary. Acta Cytologica 41 (1997) 1714-1718
22. Anttila M.A., Ji H., Juhola M.T., Saarikoski S.V., and Syrjanen K.J. The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer. Int. J. Gynecol. Pathol. 18 (1999) 42-51
23. Baekelandt M., Kristensen G.B., Nesland J.M., Trope C.G., and Holm R. Clinical significance of apoptosis-related factors p53, mdm2 and bcl-2 in advanced ovarian cancer. J. Clin. Oncol. 17 (1999) 2061-2068
24. Wen W.H., Reles A., Runnebaum I.B., et al. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int. J. Gynecol. Pathol. 18 (1999) 29-41
25. Gadducci A., Cianic C., Cosio S., et al. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. Anticancer Res. 20 (2000) 4793-4800
26. Lavarino C., Pilotti S., Oggionni M., et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J. Clin. Oncol. 18 (2000) 3936-3945
27. Ozalp S.S., Yalcin O.T., Basaran N., Artan S., Kabukcuoglu S., and Minsin T.H. Prognostic significance of deletion and over-expression of the p53 gene in epithelial ovarian cancer. Eur. J. Gynaec. Oncol. 250 (2000) 282-286
28. Schildkraut J.M., Halabi S., Bastos E., Marchbanks P.A., McDonald J.A., and Berchuck A. Prognostic factors in early-onset epithelial ovarian cancer: a population-based study. Obstet. Gynecol. 95 (2000) 119-127
29. Shahin M.S., Hughes J.H., Sood A.K., and Butler R.E. The prognostic significance of p53 tumor suppressor gene alterations in ovarian cancer. Cancer 89 (2000) 2006-2017
30. Bar J.K., Harlozinska A., Popiela A., and Noga L. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy. Tumor Biol. 22 (2001) 83-91
31. Geisler H.A., Geisler J.P., Miller G.A., Geisler M.J., Weimann M.C., Zhou Z., and Crabtree W. p21 and p53 in ovarian carcinoma. Their combined staining is more valuable than either alone. Cancer 92 (2001) 781-786
32. Howells R.E.J., Holland T., Dhar K.K., et al. Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival. Int. J. Gynecol. Cancer 11 (2001) 107-112
33. Reles A., Wen W.H., Schmider A., et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. 7 (2001) 2984-2997
34. Suzuki M., Ohwada M., Saga Y., Kohno T., Takei Y., and Sato I. Micrometastatic p53-positive cells in the lymph nodes of early stage epithelial ovarian cancer: prognostic significance. Onology 60 (2001) 170-175
35. Havrilesky L., Darcy K.M., Hamdan H., Priore R.L., Leo J., Bell J., and Berchuck A. Prognostic significance of p53 mutation of p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3814-3825
36. Okuda T., Otsuka J., Sekizawa A., et al. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol. Oncol. 88 (2003) 318-325
37. KIP1, TP53 and c-myc analysis in 204 ovarian carcinomas treated with platinum-based regimens. Annals Oncol. 14 (2003) 1078-1085
38. Wisman G.B.A., Hollema H., Helder M.N., et al. Telomerase in relation to expression of p53, c-myc and estrogen receptor in ovarian tumours. Int. J. Oncol. 23 (2003) 1451-1459
39. Hashiguchi Y., Tsuda H., Inoue T., Nishimura S., Suzuki T., and Kawamura N. Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum. Pathol. 35 (2004) 165-175
40. Dogan E., Saygili U., Tuna B., et al. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Gynecol. Oncol. 97 (2005) 46-52
41. Gadducci A., Di Cristofano C., Zavaglia M., et al. p53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel-plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res. 26 (2006) 687-694
42. de Graeff P., Hall J., Crijns A., et al. Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Brit. J. Cancer 95 (2006) 627-633
43. Bell J., Brady M., Young R., et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 102 (2006) 432-439
44. McGuire W., Hoskins W., Brady M., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
45. Vojtesek B., Bartek J., Midgley C.A., and Lane D.P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods 151 (1992) 237-244
46. Stephen C.W., Helminen P., and Lane D.P. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J. Mol. Biol. 248 (1995) 58-78
47. Deyoung M.P., and Ellisen L.W. p63 and p73 in human cancer: defining the network. Oncogene 26 (2007) 5169-5183
48. Foulkes W.D. p53-master and commander. N. Engl. J. Med. 357 (2007) 2539-2541